Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG).

ABSTRACT:

Background

Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relapsing illness due in part to an impaired host antibody response. Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some immunocompromised babesiosis patients, but its therapeutic effect is uncertain. We evaluated the presence of Babesia microti antibodies in commercial samples of IVIG.

Methods/principle findings

The presence of B. microti antibodies in commercial samples of IVIG were tested using an immunofluorescence assay. A subset of samples w

SUBMITTER: Kostka J 

PROVIDER: S-EPMC10965045 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature